文献速递血栓与止血

维生素K依赖性凝血因子缺乏症与点状软骨发育不良共病的分子机制研究

Molecular insights into the comorbidity of vitamin K-dependent clotting factor deficiency and chondrodysplasia punctata.
PubMed 文献 · J Thromb Haemost · 2025-08-26

本文报道一例携带GGCX基因两个新发复合杂合突变(c.1760A>G p.H587R和c.1787del p.P596fs)的维生素K依赖性凝血因子缺乏症患者,口服维生素K可改善凝血障碍但未能纠正钙化异常。功能分析显示P596fs变异使酶活性完全丧失,H587R对肝外维生素K依赖蛋白的损害甚于肝内蛋白,从而解释了对维生素K治疗的不同临床反应。

要点

  • 患者携带GGCX基因c.1760A>G(p.H587R)和c.1787del(p.P596fs)复合杂合突变。
  • 口服维生素K改善凝血缺陷但未纠正钙化异常相关缺陷。
  • H587R对肝外维生素K依赖蛋白的损害甚于肝内蛋白,解释治疗反应差异。

核心结论

  • 罕见患者突变可为了解GGCX生物化学提供新见解,GGCX与不同维生素K依赖蛋白的独特相互作用导致不同疾病表型。

研究设计与样本

  • 对一例维生素K依赖性凝血因子缺乏症患者进行GGCX突变鉴定,采用生物发光免疫分析、荧光共聚焦成像、分裂纳米荧光素酶互补实验和结构建模研究突变对活细胞中GGCX与多种维生素K依赖蛋白相互作用及羧化功能的影响。

主要发现

  • 患者携带两个新发复合杂合GGCX突变:c.1760A>G(p.H587R)和c.1787del(p.P596fs)。
  • 口服维生素K改善凝血缺陷,但未能纠正钙化异常相关缺陷。
  • P596fs变异使酶活性完全丧失;H587R对肝外维生素K依赖蛋白的损害甚于肝内维生素K依赖蛋白。
  • H587R显著改变GGCX与肝外维生素K依赖蛋白(如钙化抑制剂基质Gla蛋白)的结合,对肝内维生素K依赖蛋白影响较小。
  • 保守残基H587和Y601形成稳定GGCX分子的内部氢键。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autosomal recessive mutations in genes encoding vitamin K cycle enzymes cause hereditary vitamin K-dependent clotting factor deficiency, a disorder characterized by excessive bleeding and a spectrum of nonbleeding phenotypes. While high-dose vitamin K therapy can partially or fully correct coagulopathy, its effect on nonbleeding symptoms is limited. OBJECTIVES: To investigate the molecular basis underlying the differential response to vitamin K therapy, we characterized novel gamma-glutamyl carboxylase (GGCX) mutations identified in a patient with vitamin K-dependent clotting factor deficiency. METHODS: We employed bioluminescent immunoassays, fluorescence confocal imaging, split-nanoluciferase complementation assays, and structural modeling to investigate how GGCX mutations affect its interaction with, and carboxylation of, various vitamin K-dependent proteins (VKDPs) in live cells. RESULTS: The patient harbored 2 novel compound heterozygous GGCX mutations: c.1760A>G (p.H587R) and c.1787del (p.P596fs). While oral vitamin K improved coagulation deficiency, it failed to correct defects associated with calcification abnormalities. Functional analysis revealed that the P596fs variant abolished enzymatic activity, whereas H587R impaired extrahepatic VKDPs more profoundly than hepatic VKDPs, thereby explaining the distinct clinical responses to vitamin K therapy. The H587R mutation significantly altered GGCX binding to extrahepatic VKDPs, such as the calcification inhibitor matrix Gla protein, while having a lesser effect on hepatic VKDPs. Structural modeling and biochemical characterization further revealed that conserved residues H587 and Y601 form an internal hydrogen bond critical for stabilizing the GGCX molecule. CONCLUSION: These findings show how rare patient mutations can provide new insights into the biochemistry of GGCX and how its unique interactions with different VKDPs lead to distinct disease phenotypes.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Jin DY, Chen X, Wang M, et al. Molecular insights into the comorbidity of vitamin K-dependent clotting factor deficiency and chondrodysplasia punctata. J Thromb Haemost. 2025. PMID: 40876756. doi:10.1016/j.jtha.2025.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。